Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Open

11.56 -0.94

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.46

Max

12.54

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+135.25% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-80M 1B
Vorige openingsprijs	12.5
Vorige sluitingsprijs	11.56

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 sep 2026, 23:56 UTC

In after-market trading, Interactive Brokers Group Inc is roughly flat, with price fluctuations reflecting minimal movement since Wednesday's close.

23 sep 2026, 23:56 UTC

Correlated Moves

Allegiant Travel Co is trading modestly higher in after-market hours, recovering from earlier losses and currently positioned in the middle of its one-month trading range.

23 sep 2026, 23:56 UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

23 sep 2026, 23:56 UTC

Dow Inc saw a slight decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month range.

23 sep 2026, 23:55 UTC

Rush Street Interactive Inc. is trading roughly flat during after-market hours, following eight consecutive sessions with lower closes and remaining below its 20-day moving average.

23 sep 2026, 23:55 UTC

Endava PLC is seeing a slight decline in after-market trading, continuing a trend of lower daily closes and trading below its 20-day moving average.

23 sep 2026, 23:55 UTC

Delek US Holdings Inc is trading modestly higher during after-market hours, recovering from earlier declines while remaining below its 20-day moving average.

23 sep 2026, 23:55 UTC

Macro News

The U.S. Dollar Index is trading roughly flat, with macroeconomic developments highlighting oil supply from the Strait of Hormuz amid rising U.S. crude inventories.

23 sep 2026, 23:55 UTC

Cardinal Health Inc is trading modestly higher in after-market hours following slight fluctuations during the session, remaining below its 20-day moving average.

23 sep 2026, 23:52 UTC

Northrop Grumman Corp is declining in after-market trading, settling lower after briefly turning positive and remaining below its 20-day moving average.

23 sep 2026, 23:52 UTC

South Africa's Balance of Trade Data Release on September 30: Market Eyes Sustained Surplus Amid Mixed Economic Signals.

23 sep 2026, 23:52 UTC

Germany's Inflation Rate Expected to Remain Stable Ahead of September 30 Release Amid Geopolitical Tensions and Strong Manufacturing Activity

23 sep 2026, 23:52 UTC

Germany's Inflation Rate Release on September 30 Expected to Show Stability Amid Strong Manufacturing Growth and Geopolitical Tensions.

23 sep 2026, 23:52 UTC

Mixed Sentiment Ahead of U.S. New Home Sales Data Release Amidst Slowing Activity and Luxury Market Resilience

23 sep 2026, 23:52 UTC

New Home Sales Expected at 0.62 Million Amid Rising Prices and Cautious Market Sentiment

23 sep 2026, 23:52 UTC

Japan's Tankan Large Manufacturers Index set for release on September 30, amid mixed market sentiments influenced by global economic factors and rising interest rate concerns.

23 sep 2026, 23:51 UTC

Cleveland-Cliffs Inc has traded lower in after-market hours, pulling back from earlier highs while remaining above its 20-day moving average.

23 sep 2026, 23:51 UTC

Urban Outfitters Inc. is declining in after-market trading, falling significantly below its 20-day moving average and nearing the lower end of its one-month range.

23 sep 2026, 23:51 UTC

Guidewire Software Inc's shares are trading modestly higher in after-market hours, continuing a trend of gradual increases since Wednesday's close.

23 sep 2026, 23:51 UTC

Conagra Brands Inc is seeing modest declines in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

23 sep 2026, 23:51 UTC

Frontdoor Inc's shares advanced modestly in after-market trading, achieving nearly a 1% cumulative return since Wednesday's close, despite trading near the lower end of its range.

23 sep 2026, 23:51 UTC

Nu Holdings Ltd. saw a modest increase in after-market trading, recovering from a low point and marking a cumulative return of nearly 1%.

23 sep 2026, 23:51 UTC

West Pharmaceutical Services Inc is seeing a modest decline in after-market trading, positioned at the lower end of today's range but above its 20-day moving average.

23 sep 2026, 23:51 UTC

Cable One Inc is trading modestly higher in after-market hours, following a notable peak shortly after the regular session ended.

23 sep 2026, 23:51 UTC

Vertex Pharmaceuticals Inc saw a modest rise in after-market trading, recovering from a low return shortly after the market closed.

23 sep 2026, 23:46 UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

23 sep 2026, 23:46 UTC

Boyd Gaming Corp declined in after-market trading, moving from a slight gain to a loss, and is significantly below its 20-day moving average.

23 sep 2026, 23:46 UTC

Repligen Corp's stock declined in after-market trading, hitting its lowest point of the day after Wednesday's close, despite remaining above its 20-day moving average.

23 sep 2026, 23:46 UTC

CEVA Inc is trading modestly higher in after-market hours, maintaining strength above its 20-day moving average amid positive private sector activity indicators.

23 sep 2026, 23:46 UTC

Sirius XM Holdings Inc is down in after-market trading, marking four consecutive sessions of declines and remaining below its 20-day moving average.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

135.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 135.25%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.